Global Rosacea Drugs Market
Global Rosacea Drugs Market

Rosacea Drugs Comprehensive Study by Type (Antibiotics, Alpha agonists, Retinoids, Corticosteroids, Immunosuppressants, Antihypertensive Agents, Others), Mode of Administration (Topical, Orals), Distribution Channel (Drugs Stores, Hospital, Other) Players and Region - Global Market Outlook to 2026

Rosacea Drugs Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Jan 2021 Edition 227 Pages 184 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Rosacea Drugs Market Overview:
Rosacea is a disorder involving chronic inflammation of the cheeks, nose, chin, forehead, or eyelids. It may cause redness, vascularity, swelling or hyperplasia, or skin eruptions similar to acne. The main symptoms of rosacea are facial flushing, irritated skin, and pimples. Other symptoms include blushing easily and eye problems.

Growth Drivers
  • Rising Awareness about Rosacea
  • High Demand for Effective Treatment for Parkinson's Disease

Market Trends
  • Increased Research and Development Activities

Roadblocks
  • Side Effects of the Drugs

Opportunities
  • Growth in the Geriatric Population Worldwide
  • Growth in the Healthcare Sector

Challenges
  • Multiple Patent Expiries Bring a Significant Number of Generic Products


Competitive Landscape:
The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations.
Some of the key players profiled in the report are Nestle Skin Health (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Mylan (United States), Bayer (Germany), Sun Pharma (India), Perrigo (United States), Bausch Health (Canada), GSK (United Kingdom) and Pfizer (United States). Additionally, following companies can also be profiled that are part of our coverage like Allergan (Ireland) and Almirall (Spain). Analyst at AMA Research see Global Players to retain maximum share of Global Rosacea Drugs market by 2026. Considering Market by Mode of Administration, the sub-segment i.e. Topical will boost the Rosacea Drugs market. Considering Market by Distribution Channel, the sub-segment i.e. Drugs Stores will boost the Rosacea Drugs market.

In Sept 2020, Sol-Gel Technologies, Ltd. announced that its New Drug Application (NDA) for Epsolay® (benzoyl peroxide), an investigational proprietary topical cream for the treatment of inflammatory lesions of rosacea, containing 5% encapsulated benzoyl peroxide, has been accepted for filing by the U.S. Food and Drug Administration (FDA). The Prescription Drug User Fee Act (PDUFA) goal date assigned by the FDA for Epsolay is April 26, 2021.

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Rosacea Drugs market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Rosacea Drugs market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Manufacturers of Rosacea Drugs, Suppliers and Distributors of Rosacea Drugs, End-Users, Potential Investors, Market Research Firms, Regulatory Bodies and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Type
  • Antibiotics
  • Alpha agonists
  • Retinoids
  • Corticosteroids
  • Immunosuppressants
  • Antihypertensive Agents
  • Others
By Mode of Administration
  • Topical
  • Orals

By Distribution Channel
  • Drugs Stores
  • Hospital
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Awareness about Rosacea
      • 3.2.2. High Demand for Effective Treatment for Parkinson's Disease
    • 3.3. Market Challenges
      • 3.3.1. Multiple Patent Expiries Bring a Significant Number of Generic Products
    • 3.4. Market Trends
      • 3.4.1. Increased Research and Development Activities
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Rosacea Drugs, by Type, Mode of Administration, Distribution Channel and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Rosacea Drugs (Value)
      • 5.2.1. Global Rosacea Drugs by: Type (Value)
        • 5.2.1.1. Antibiotics
        • 5.2.1.2. Alpha agonists
        • 5.2.1.3. Retinoids
        • 5.2.1.4. Corticosteroids
        • 5.2.1.5. Immunosuppressants
        • 5.2.1.6. Antihypertensive Agents
        • 5.2.1.7. Others
      • 5.2.2. Global Rosacea Drugs by: Mode of Administration (Value)
        • 5.2.2.1. Topical
        • 5.2.2.2. Orals
      • 5.2.3. Global Rosacea Drugs by: Distribution Channel (Value)
        • 5.2.3.1. Drugs Stores
        • 5.2.3.2. Hospital
        • 5.2.3.3. Other
      • 5.2.4. Global Rosacea Drugs Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Rosacea Drugs (Price)
      • 5.3.1. Global Rosacea Drugs by: Type (Price)
  • 6. Rosacea Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Nestle Skin Health (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Mylan (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bayer (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sun Pharma (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Perrigo (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Bausch Health (Canada)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. GSK (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Pfizer (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Rosacea Drugs Sale, by Type, Mode of Administration, Distribution Channel and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Rosacea Drugs (Value)
      • 7.2.1. Global Rosacea Drugs by: Type (Value)
        • 7.2.1.1. Antibiotics
        • 7.2.1.2. Alpha agonists
        • 7.2.1.3. Retinoids
        • 7.2.1.4. Corticosteroids
        • 7.2.1.5. Immunosuppressants
        • 7.2.1.6. Antihypertensive Agents
        • 7.2.1.7. Others
      • 7.2.2. Global Rosacea Drugs by: Mode of Administration (Value)
        • 7.2.2.1. Topical
        • 7.2.2.2. Orals
      • 7.2.3. Global Rosacea Drugs by: Distribution Channel (Value)
        • 7.2.3.1. Drugs Stores
        • 7.2.3.2. Hospital
        • 7.2.3.3. Other
      • 7.2.4. Global Rosacea Drugs Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Rosacea Drugs (Price)
      • 7.3.1. Global Rosacea Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Rosacea Drugs: by Type(USD Million)
  • Table 2. Rosacea Drugs Antibiotics , by Region USD Million (2015-2020)
  • Table 3. Rosacea Drugs Alpha agonists , by Region USD Million (2015-2020)
  • Table 4. Rosacea Drugs Retinoids , by Region USD Million (2015-2020)
  • Table 5. Rosacea Drugs Corticosteroids , by Region USD Million (2015-2020)
  • Table 6. Rosacea Drugs Immunosuppressants , by Region USD Million (2015-2020)
  • Table 7. Rosacea Drugs Antihypertensive Agents , by Region USD Million (2015-2020)
  • Table 8. Rosacea Drugs Others , by Region USD Million (2015-2020)
  • Table 9. Rosacea Drugs: by Mode of Administration(USD Million)
  • Table 10. Rosacea Drugs Topical , by Region USD Million (2015-2020)
  • Table 11. Rosacea Drugs Orals , by Region USD Million (2015-2020)
  • Table 12. Rosacea Drugs: by Distribution Channel(USD Million)
  • Table 13. Rosacea Drugs Drugs Stores , by Region USD Million (2015-2020)
  • Table 14. Rosacea Drugs Hospital , by Region USD Million (2015-2020)
  • Table 15. Rosacea Drugs Other , by Region USD Million (2015-2020)
  • Table 16. South America Rosacea Drugs, by Country USD Million (2015-2020)
  • Table 17. South America Rosacea Drugs, by Type USD Million (2015-2020)
  • Table 18. South America Rosacea Drugs, by Mode of Administration USD Million (2015-2020)
  • Table 19. South America Rosacea Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 20. Brazil Rosacea Drugs, by Type USD Million (2015-2020)
  • Table 21. Brazil Rosacea Drugs, by Mode of Administration USD Million (2015-2020)
  • Table 22. Brazil Rosacea Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 23. Argentina Rosacea Drugs, by Type USD Million (2015-2020)
  • Table 24. Argentina Rosacea Drugs, by Mode of Administration USD Million (2015-2020)
  • Table 25. Argentina Rosacea Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 26. Rest of South America Rosacea Drugs, by Type USD Million (2015-2020)
  • Table 27. Rest of South America Rosacea Drugs, by Mode of Administration USD Million (2015-2020)
  • Table 28. Rest of South America Rosacea Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 29. Asia Pacific Rosacea Drugs, by Country USD Million (2015-2020)
  • Table 30. Asia Pacific Rosacea Drugs, by Type USD Million (2015-2020)
  • Table 31. Asia Pacific Rosacea Drugs, by Mode of Administration USD Million (2015-2020)
  • Table 32. Asia Pacific Rosacea Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 33. China Rosacea Drugs, by Type USD Million (2015-2020)
  • Table 34. China Rosacea Drugs, by Mode of Administration USD Million (2015-2020)
  • Table 35. China Rosacea Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 36. Japan Rosacea Drugs, by Type USD Million (2015-2020)
  • Table 37. Japan Rosacea Drugs, by Mode of Administration USD Million (2015-2020)
  • Table 38. Japan Rosacea Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 39. India Rosacea Drugs, by Type USD Million (2015-2020)
  • Table 40. India Rosacea Drugs, by Mode of Administration USD Million (2015-2020)
  • Table 41. India Rosacea Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 42. South Korea Rosacea Drugs, by Type USD Million (2015-2020)
  • Table 43. South Korea Rosacea Drugs, by Mode of Administration USD Million (2015-2020)
  • Table 44. South Korea Rosacea Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 45. Taiwan Rosacea Drugs, by Type USD Million (2015-2020)
  • Table 46. Taiwan Rosacea Drugs, by Mode of Administration USD Million (2015-2020)
  • Table 47. Taiwan Rosacea Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 48. Australia Rosacea Drugs, by Type USD Million (2015-2020)
  • Table 49. Australia Rosacea Drugs, by Mode of Administration USD Million (2015-2020)
  • Table 50. Australia Rosacea Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 51. Rest of Asia-Pacific Rosacea Drugs, by Type USD Million (2015-2020)
  • Table 52. Rest of Asia-Pacific Rosacea Drugs, by Mode of Administration USD Million (2015-2020)
  • Table 53. Rest of Asia-Pacific Rosacea Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 54. Europe Rosacea Drugs, by Country USD Million (2015-2020)
  • Table 55. Europe Rosacea Drugs, by Type USD Million (2015-2020)
  • Table 56. Europe Rosacea Drugs, by Mode of Administration USD Million (2015-2020)
  • Table 57. Europe Rosacea Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 58. Germany Rosacea Drugs, by Type USD Million (2015-2020)
  • Table 59. Germany Rosacea Drugs, by Mode of Administration USD Million (2015-2020)
  • Table 60. Germany Rosacea Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 61. France Rosacea Drugs, by Type USD Million (2015-2020)
  • Table 62. France Rosacea Drugs, by Mode of Administration USD Million (2015-2020)
  • Table 63. France Rosacea Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 64. Italy Rosacea Drugs, by Type USD Million (2015-2020)
  • Table 65. Italy Rosacea Drugs, by Mode of Administration USD Million (2015-2020)
  • Table 66. Italy Rosacea Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 67. United Kingdom Rosacea Drugs, by Type USD Million (2015-2020)
  • Table 68. United Kingdom Rosacea Drugs, by Mode of Administration USD Million (2015-2020)
  • Table 69. United Kingdom Rosacea Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 70. Netherlands Rosacea Drugs, by Type USD Million (2015-2020)
  • Table 71. Netherlands Rosacea Drugs, by Mode of Administration USD Million (2015-2020)
  • Table 72. Netherlands Rosacea Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 73. Rest of Europe Rosacea Drugs, by Type USD Million (2015-2020)
  • Table 74. Rest of Europe Rosacea Drugs, by Mode of Administration USD Million (2015-2020)
  • Table 75. Rest of Europe Rosacea Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 76. MEA Rosacea Drugs, by Country USD Million (2015-2020)
  • Table 77. MEA Rosacea Drugs, by Type USD Million (2015-2020)
  • Table 78. MEA Rosacea Drugs, by Mode of Administration USD Million (2015-2020)
  • Table 79. MEA Rosacea Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 80. Middle East Rosacea Drugs, by Type USD Million (2015-2020)
  • Table 81. Middle East Rosacea Drugs, by Mode of Administration USD Million (2015-2020)
  • Table 82. Middle East Rosacea Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 83. Africa Rosacea Drugs, by Type USD Million (2015-2020)
  • Table 84. Africa Rosacea Drugs, by Mode of Administration USD Million (2015-2020)
  • Table 85. Africa Rosacea Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 86. North America Rosacea Drugs, by Country USD Million (2015-2020)
  • Table 87. North America Rosacea Drugs, by Type USD Million (2015-2020)
  • Table 88. North America Rosacea Drugs, by Mode of Administration USD Million (2015-2020)
  • Table 89. North America Rosacea Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 90. United States Rosacea Drugs, by Type USD Million (2015-2020)
  • Table 91. United States Rosacea Drugs, by Mode of Administration USD Million (2015-2020)
  • Table 92. United States Rosacea Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 93. Canada Rosacea Drugs, by Type USD Million (2015-2020)
  • Table 94. Canada Rosacea Drugs, by Mode of Administration USD Million (2015-2020)
  • Table 95. Canada Rosacea Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 96. Mexico Rosacea Drugs, by Type USD Million (2015-2020)
  • Table 97. Mexico Rosacea Drugs, by Mode of Administration USD Million (2015-2020)
  • Table 98. Mexico Rosacea Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 99. Rosacea Drugs: by Type(USD/Units)
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Rosacea Drugs: by Type(USD Million)
  • Table 110. Rosacea Drugs Antibiotics , by Region USD Million (2021-2026)
  • Table 111. Rosacea Drugs Alpha agonists , by Region USD Million (2021-2026)
  • Table 112. Rosacea Drugs Retinoids , by Region USD Million (2021-2026)
  • Table 113. Rosacea Drugs Corticosteroids , by Region USD Million (2021-2026)
  • Table 114. Rosacea Drugs Immunosuppressants , by Region USD Million (2021-2026)
  • Table 115. Rosacea Drugs Antihypertensive Agents , by Region USD Million (2021-2026)
  • Table 116. Rosacea Drugs Others , by Region USD Million (2021-2026)
  • Table 117. Rosacea Drugs: by Mode of Administration(USD Million)
  • Table 118. Rosacea Drugs Topical , by Region USD Million (2021-2026)
  • Table 119. Rosacea Drugs Orals , by Region USD Million (2021-2026)
  • Table 120. Rosacea Drugs: by Distribution Channel(USD Million)
  • Table 121. Rosacea Drugs Drugs Stores , by Region USD Million (2021-2026)
  • Table 122. Rosacea Drugs Hospital , by Region USD Million (2021-2026)
  • Table 123. Rosacea Drugs Other , by Region USD Million (2021-2026)
  • Table 124. South America Rosacea Drugs, by Country USD Million (2021-2026)
  • Table 125. South America Rosacea Drugs, by Type USD Million (2021-2026)
  • Table 126. South America Rosacea Drugs, by Mode of Administration USD Million (2021-2026)
  • Table 127. South America Rosacea Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 128. Brazil Rosacea Drugs, by Type USD Million (2021-2026)
  • Table 129. Brazil Rosacea Drugs, by Mode of Administration USD Million (2021-2026)
  • Table 130. Brazil Rosacea Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 131. Argentina Rosacea Drugs, by Type USD Million (2021-2026)
  • Table 132. Argentina Rosacea Drugs, by Mode of Administration USD Million (2021-2026)
  • Table 133. Argentina Rosacea Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 134. Rest of South America Rosacea Drugs, by Type USD Million (2021-2026)
  • Table 135. Rest of South America Rosacea Drugs, by Mode of Administration USD Million (2021-2026)
  • Table 136. Rest of South America Rosacea Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 137. Asia Pacific Rosacea Drugs, by Country USD Million (2021-2026)
  • Table 138. Asia Pacific Rosacea Drugs, by Type USD Million (2021-2026)
  • Table 139. Asia Pacific Rosacea Drugs, by Mode of Administration USD Million (2021-2026)
  • Table 140. Asia Pacific Rosacea Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 141. China Rosacea Drugs, by Type USD Million (2021-2026)
  • Table 142. China Rosacea Drugs, by Mode of Administration USD Million (2021-2026)
  • Table 143. China Rosacea Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 144. Japan Rosacea Drugs, by Type USD Million (2021-2026)
  • Table 145. Japan Rosacea Drugs, by Mode of Administration USD Million (2021-2026)
  • Table 146. Japan Rosacea Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 147. India Rosacea Drugs, by Type USD Million (2021-2026)
  • Table 148. India Rosacea Drugs, by Mode of Administration USD Million (2021-2026)
  • Table 149. India Rosacea Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 150. South Korea Rosacea Drugs, by Type USD Million (2021-2026)
  • Table 151. South Korea Rosacea Drugs, by Mode of Administration USD Million (2021-2026)
  • Table 152. South Korea Rosacea Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 153. Taiwan Rosacea Drugs, by Type USD Million (2021-2026)
  • Table 154. Taiwan Rosacea Drugs, by Mode of Administration USD Million (2021-2026)
  • Table 155. Taiwan Rosacea Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 156. Australia Rosacea Drugs, by Type USD Million (2021-2026)
  • Table 157. Australia Rosacea Drugs, by Mode of Administration USD Million (2021-2026)
  • Table 158. Australia Rosacea Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 159. Rest of Asia-Pacific Rosacea Drugs, by Type USD Million (2021-2026)
  • Table 160. Rest of Asia-Pacific Rosacea Drugs, by Mode of Administration USD Million (2021-2026)
  • Table 161. Rest of Asia-Pacific Rosacea Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 162. Europe Rosacea Drugs, by Country USD Million (2021-2026)
  • Table 163. Europe Rosacea Drugs, by Type USD Million (2021-2026)
  • Table 164. Europe Rosacea Drugs, by Mode of Administration USD Million (2021-2026)
  • Table 165. Europe Rosacea Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 166. Germany Rosacea Drugs, by Type USD Million (2021-2026)
  • Table 167. Germany Rosacea Drugs, by Mode of Administration USD Million (2021-2026)
  • Table 168. Germany Rosacea Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 169. France Rosacea Drugs, by Type USD Million (2021-2026)
  • Table 170. France Rosacea Drugs, by Mode of Administration USD Million (2021-2026)
  • Table 171. France Rosacea Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 172. Italy Rosacea Drugs, by Type USD Million (2021-2026)
  • Table 173. Italy Rosacea Drugs, by Mode of Administration USD Million (2021-2026)
  • Table 174. Italy Rosacea Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 175. United Kingdom Rosacea Drugs, by Type USD Million (2021-2026)
  • Table 176. United Kingdom Rosacea Drugs, by Mode of Administration USD Million (2021-2026)
  • Table 177. United Kingdom Rosacea Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 178. Netherlands Rosacea Drugs, by Type USD Million (2021-2026)
  • Table 179. Netherlands Rosacea Drugs, by Mode of Administration USD Million (2021-2026)
  • Table 180. Netherlands Rosacea Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 181. Rest of Europe Rosacea Drugs, by Type USD Million (2021-2026)
  • Table 182. Rest of Europe Rosacea Drugs, by Mode of Administration USD Million (2021-2026)
  • Table 183. Rest of Europe Rosacea Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 184. MEA Rosacea Drugs, by Country USD Million (2021-2026)
  • Table 185. MEA Rosacea Drugs, by Type USD Million (2021-2026)
  • Table 186. MEA Rosacea Drugs, by Mode of Administration USD Million (2021-2026)
  • Table 187. MEA Rosacea Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 188. Middle East Rosacea Drugs, by Type USD Million (2021-2026)
  • Table 189. Middle East Rosacea Drugs, by Mode of Administration USD Million (2021-2026)
  • Table 190. Middle East Rosacea Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 191. Africa Rosacea Drugs, by Type USD Million (2021-2026)
  • Table 192. Africa Rosacea Drugs, by Mode of Administration USD Million (2021-2026)
  • Table 193. Africa Rosacea Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 194. North America Rosacea Drugs, by Country USD Million (2021-2026)
  • Table 195. North America Rosacea Drugs, by Type USD Million (2021-2026)
  • Table 196. North America Rosacea Drugs, by Mode of Administration USD Million (2021-2026)
  • Table 197. North America Rosacea Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 198. United States Rosacea Drugs, by Type USD Million (2021-2026)
  • Table 199. United States Rosacea Drugs, by Mode of Administration USD Million (2021-2026)
  • Table 200. United States Rosacea Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 201. Canada Rosacea Drugs, by Type USD Million (2021-2026)
  • Table 202. Canada Rosacea Drugs, by Mode of Administration USD Million (2021-2026)
  • Table 203. Canada Rosacea Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 204. Mexico Rosacea Drugs, by Type USD Million (2021-2026)
  • Table 205. Mexico Rosacea Drugs, by Mode of Administration USD Million (2021-2026)
  • Table 206. Mexico Rosacea Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 207. Rosacea Drugs: by Type(USD/Units)
  • Table 208. Research Programs/Design for This Report
  • Table 209. Key Data Information from Secondary Sources
  • Table 210. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Rosacea Drugs: by Type USD Million (2015-2020)
  • Figure 5. Global Rosacea Drugs: by Mode of Administration USD Million (2015-2020)
  • Figure 6. Global Rosacea Drugs: by Distribution Channel USD Million (2015-2020)
  • Figure 7. South America Rosacea Drugs Share (%), by Country
  • Figure 8. Asia Pacific Rosacea Drugs Share (%), by Country
  • Figure 9. Europe Rosacea Drugs Share (%), by Country
  • Figure 10. MEA Rosacea Drugs Share (%), by Country
  • Figure 11. North America Rosacea Drugs Share (%), by Country
  • Figure 12. Global Rosacea Drugs: by Type USD/Units (2015-2020)
  • Figure 13. Global Rosacea Drugs share by Players 2020 (%)
  • Figure 14. Global Rosacea Drugs share by Players (Top 3) 2020(%)
  • Figure 15. Global Rosacea Drugs share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Nestle Skin Health (Switzerland) Revenue, Net Income and Gross profit
  • Figure 18. Nestle Skin Health (Switzerland) Revenue: by Geography 2020
  • Figure 19. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 20. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2020
  • Figure 21. Mylan (United States) Revenue, Net Income and Gross profit
  • Figure 22. Mylan (United States) Revenue: by Geography 2020
  • Figure 23. Bayer (Germany) Revenue, Net Income and Gross profit
  • Figure 24. Bayer (Germany) Revenue: by Geography 2020
  • Figure 25. Sun Pharma (India) Revenue, Net Income and Gross profit
  • Figure 26. Sun Pharma (India) Revenue: by Geography 2020
  • Figure 27. Perrigo (United States) Revenue, Net Income and Gross profit
  • Figure 28. Perrigo (United States) Revenue: by Geography 2020
  • Figure 29. Bausch Health (Canada) Revenue, Net Income and Gross profit
  • Figure 30. Bausch Health (Canada) Revenue: by Geography 2020
  • Figure 31. GSK (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 32. GSK (United Kingdom) Revenue: by Geography 2020
  • Figure 33. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 34. Pfizer (United States) Revenue: by Geography 2020
  • Figure 35. Global Rosacea Drugs: by Type USD Million (2021-2026)
  • Figure 36. Global Rosacea Drugs: by Mode of Administration USD Million (2021-2026)
  • Figure 37. Global Rosacea Drugs: by Distribution Channel USD Million (2021-2026)
  • Figure 38. South America Rosacea Drugs Share (%), by Country
  • Figure 39. Asia Pacific Rosacea Drugs Share (%), by Country
  • Figure 40. Europe Rosacea Drugs Share (%), by Country
  • Figure 41. MEA Rosacea Drugs Share (%), by Country
  • Figure 42. North America Rosacea Drugs Share (%), by Country
  • Figure 43. Global Rosacea Drugs: by Type USD/Units (2021-2026)
Some of the key companies/manufacturers profiled in the report
  • Nestle Skin Health (Switzerland)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Mylan (United States)
  • Bayer (Germany)
  • Sun Pharma (India)
  • Perrigo (United States)
  • Bausch Health (Canada)
  • GSK (United Kingdom)
  • Pfizer (United States)
Additional players considered in the study are as follows:
Allergan (Ireland) , Almirall (Spain)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation